## Mathieu F Chevalier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5077229/publications.pdf

Version: 2024-02-01

471061 476904 32 1,428 17 29 citations h-index g-index papers 32 32 32 2624 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients. European Urology Focus, 2022, 8, 748-751.	1.6	6
2	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. Cancer Discovery, 2022, 12, 958-983.	7.7	10
3	Real-world characteristics of T-cell apheresis and clinical response toÂtisagenlecleucel in B-cell lymphoma. Blood Advances, 2022, 6, 4657-4660.	2.5	11
4	Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse. Blood, 2022, 140, 1305-1321.	0.6	23
5	Association of Plasma Soluble Vascular Cell Adhesion Molecule-1 and sCD14 With Mortality in HIV-1â€"Infected West African Adults With High CD4 Counts. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 138-145.	0.9	6
6	Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy., 2021, 9,.		2
7	Siglec-7 May Limit Natural Killer Cell–mediated Antitumor responses in Bladder Cancer Patients. European Urology Open Science, 2021, 34, 79-82.	0.2	5
8	Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy., 2021, 9, e003123.		11
9	The multifaceted immune regulation of bladder cancer. Nature Reviews Urology, 2019, 16, 613-630.	1.9	123
10	Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell–Mediated Tumor Regression in the MB49 Bladder Cancer Model. Cancer Immunology Research, 2019, 7, 621-629.	1.6	26
11	The pro- and anti-tumor role of ILC2s. Seminars in Immunology, 2019, 41, 101276.	2.7	19
12	Double Positive CD4+CD8+ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization. Frontiers in Immunology, 2019, 10, 622.	2.2	55
13	Î3Î^T-cell subsets in HIV controllers. Aids, 2019, 33, 1283-1292.	1.0	22
14	Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy. European Urology, 2018, 74, 540-544.	0.9	53
15	Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer. Oncolmmunology, 2017, 6, e1265720.	2.1	19
16	Interleukin-1 receptor antagonist, a biomarker of response to anti-TB treatment in HIV/TB co-infected patients. Journal of Infection, 2017, 74, 456-465.	1.7	9
17	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature Communications, 2017, 8, 593.	5.8	175
18	Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer. European Urology, 2017, 71, 854-857.	0.9	22

#	Article	IF	CITATIONS
19	ILC2-modulated T cell–to-MDSC balance is associated with bladder cancer recurrence. Journal of Clinical Investigation, 2017, 127, 2916-2929.	3.9	176
20	CD4 T-Cell Responses in Primary HIV Infection: Interrelationship with Immune Activation and Virus Burden. Frontiers in Immunology, 2016, 7, 395.	2.2	17
21	Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 390-398.	0.9	10
22	Phenotype Alterations in Regulatory T-Cell Subsets in Primary HIV Infection and Identification of Tr1-like Cells as the Main Interleukin 10-Producing CD4+ T Cells. Journal of Infectious Diseases, 2015, 211, 769-779.	1.9	37
23	Local <i>Salmonella</i> inmunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor. Oncolmmunology, 2015, 4, e1016697.	2.1	11
24	High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. Oncolmmunology, 2015, 4, e1029702.	2.1	17
25	Immunotherapeutic strategies for bladder cancer. Human Vaccines and Immunotherapeutics, 2014, 10, 977-981.	1.4	6
26	T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection. Aids, 2014, 28, 1683-1687.	1.0	18
27	The split personality of regulatory T cells in HIV infection. Blood, 2013, 121, 29-37.	0.6	192
28	The Th17/Treg Ratio, IL-1RA and sCD14 Levels in Primary HIV Infection Predict the T-cell Activation Set Point in the Absence of Systemic Microbial Translocation. PLoS Pathogens, 2013, 9, e1003453.	2.1	91
29	Level of double negative T cells, which produce TGF- $\hat{l}^2$ and IL-10, predicts CD8 T-cell activation in primary HIV-1 infection. Aids, 2012, 26, 139-148.	1.0	52
30	The early Th17/Treg ratio predicts the immune activation set point in patients with primary HIV infection. Retrovirology, 2012, 9, .	0.9	0
31	HIV-1-Specific Interleukin-21 <sup>+</sup> CD4 <sup>+</sup> T Cell Responses Contribute to Durable Viral Control through the Modulation of HIV-Specific CD8 <sup>+</sup> T Cell Function. Journal of Virology, 2011, 85, 733-741.	1.5	173
32	Epithelial adhesion molecules can inhibit HIV-1–specific CD8+ T-cell functions. Blood, 2011, 117, 5112-5122.	0.6	31